At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
SCY-078 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label, Randomized Study to Estimate Safety, PK, and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Standard-of-Care Following IV Echinocandin Therapy in the Treatment of Invasive Candidiasis in Hospitalized Nonneutropenic Adults
In Brief
A Phase 2 clinical trial evaluating SCY-078, Fluconazole, and 1 other intervention for Mycoses and 2 related conditions. Completed, enrolled 27 participants across 30 sites in 5 countries.
Detailed Summary
The purpose of this study is to compare the safety, pharmacokinetics, and efficacy of oral SCY-078 vs. standard-of-care following initial intravenous echinocandin therapy in the treatment of invasive candidiasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMycoses, Candidiasis, Invasive, Candidemia
CountriesEl Salvador, Germany, Guatemala, Honduras, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedSep 2014
Primary CompletionJun 2016
Study CompletionAug 2016
TodayJul 2026
First PostedSep 19, 2014
Enrollment StartSep 1, 2014
Primary CompletionJun 1, 2016
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.8 years ago
Interventions
SCY-078drug
Fluconazoledrug
Micafungindrug